Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
133.5 ^USD	+0.25%		-2.73%	+5.96%

May. 10	Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing	MT
May. 06	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT

Specialised Therapeutics Signs Exclusive Agreement with Ascendis Pharma A/S for Distribution and Commercialisation of Three Endocrinology Therapies in Australia and Select South-East Asia Countries

January 07, 2024 at 02:00 pm EST

Specialised Therapeutics Asia Pte Ltd. (ST) has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma A/S. Under the terms of the agreement, ST will commercialise Ascendis Pharma's weekly injectable paediatric human growth hormone treatment SKYTROFATM (lonapegsomatropin), hypoparathyroidism treatment YORVIPATHTM (palopegteriparatide) and investigational achondroplasia therapy TransCon? CNP (navepegritide). The third product ?

TransCon CNP ? is in development by Ascendis Pharma for the treatment of achondroplasia (ACH), the most common genetic form of skeletal dysplasia and resulting disproportionate short stature, following successful Phase 2 trial results.

Latest news about Ascendis Pharma A/S

Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing	May. 10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
Ascendis Pharma Q1 Net Loss Widens, Revenue Rises	May. 03	MT
Transcript : Ascendis Pharma A/S, Q1 2024 Earnings Call, May 02, 2024	May. 02
Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	Apr. 24	MT
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	Feb. 29	CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	Feb. 16	MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	Feb. 09	MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating	Feb. 08	MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating	Feb. 08	MT

Chart Ascendis Pharma A/S

Duration

Period

More charts

Company Profile

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Sector

Biotechnology & Medical Research

Calendar

08:50am - European Endocrinology of Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

123.9 EUR

Average target price

167.3 EUR

Spread / Average Target

+34.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENDIS PHARMA A/S	+5.96%	7.62B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs